Skip to content

Checked

DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT04920617 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 2
Interventional
Planned enrollment
102
Participants, all sites
U.S. sites
17
In 11 states

Study details

Conditions
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.) (Industry)
Ages
18 years and older
Sex
All
Healthy volunteers
Not accepted
Start
06/18/2021
Primary completion (expected)
October 2024
Last updated by sponsor
04/07/2023

Full eligibility rules, contacts and site names: NCT04920617 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • California: Fountain Valley
  • Florida: Boca Raton, Hollywood, Plantation, St. Petersburg
  • Georgia: Atlanta
  • Indiana: Indianapolis
  • Louisiana: New Orleans
  • Nebraska: Omaha
  • New Mexico: Santa Fe
  • North Carolina: Greenville
  • Ohio: Toledo (2), Canton
  • Pennsylvania: Pittsburgh, West Reading
  • South Dakota: Watertown

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 04/07/2023